Biological characterization of sPV1(M). Plaque reduction assay in the presence (+) and absence (−) of antibodies as described in (13). Anti-PV1(M) and anti-PV2(L) are neutralizing polyclonal antibodies specific for types 1 and 2 poliovirus, respectively. Neuropathogenicity of sPV1(M) andwt PV1(M) was assayed in hPVR-tg mice as described in (13). PLD50 is defined as the amount of virus that caused paralysis or death in 50% of the inoculated mice.
Virus | PFU | PLD50(log10 PFU) | |||||
---|---|---|---|---|---|---|---|
Mab D171 | Anti-PV1(M) | Anti-PV2(L) | |||||
– | + | – | + | – | + | ||
sPV1(M) | 83 | 0 | 91 | 0 | 88 | 92 | 6.2 |
wt PV1(M) | 89 | 0 | 86 | 0 | 90 | 87 | 2.0 |